Abstract
Clopidogrel is an inactive prodrug that is converted into the active metabolites by the cytochrome P-450 (CYP) system. The impact of coadministration of statin and clopidogrel on platelet inhibition is controversial, which may result from assessment during early period statin use, differences in assays used, and the selection of high posttreatment platelet reactivity (HPPR) and normal responders to clopidogrel. During chronic phase of coadministration of statin and clopidogrel, the influence of CYP3A4 vs non-CYP3A4 metabolized statin on platelet inhibition has not been evaluated.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
